Provided by Tiger Trade Technology Pte. Ltd.

Oric Pharmaceuticals Inc.

13.80
-0.4000-2.82%
Volume:605.03K
Turnover:8.36M
Market Cap:1.43B
PE:-10.21
High:14.52
Open:14.16
Low:13.56
Close:14.20
52wk High:14.93
52wk Low:7.23
Shares:103.52M
Float Shares:88.69M
Volume Ratio:0.62
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3513
EPS(LYR):-1.4747
ROE:-39.80%
ROA:-25.97%
PB:3.75
PE(LYR):-9.36

Loading ...

Oric Pharmaceuticals to present rinzimetostat preclinical data at AACR Annual Meeting

Reuters
·
Mar 18

ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire
·
Mar 18

A Look At ORIC Pharmaceuticals (ORIC) Valuation After Competitor Tazverik Withdrawal And Analyst Support

Simply Wall St.
·
Mar 15

Oric Pharmaceuticals Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 13

Constructive Buy Thesis on ORIC Driven by Differentiated PRC2 Biology and Manageable Safety Profile for Rinzimetostat

TIPRANKS
·
Mar 10

Cantor says Oric move down on tazemetostat withdrawal an ‘over-reaction’

TIPRANKS
·
Mar 10

Oric Pharmaceuticals falls after peer Ipsen voluntarily withdraws Tazverik

TIPRANKS
·
Mar 09

Oric Pharmaceuticals Reports Nasdaq Inducement Equity Grants for New Employee

Reuters
·
Mar 07

Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Mar 07

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 07

Oric Pharmaceuticals CFO Dominic Piscitelli Disposes of Common Shares

Reuters
·
Feb 27

A Look At ORIC Pharmaceuticals (ORIC) Valuation After Phase 1b Results And Extended Cash Runway

Simply Wall St.
·
Feb 25

Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright

TIPRANKS
·
Feb 24

Oric Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $25 From $23

THOMSON REUTERS
·
Feb 24

Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush

Dow Jones
·
Feb 24

Oppenheimer Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC)

TIPRANKS
·
Feb 24

Oric Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Feb 24

Oric Pharmaceuticals Launches New 2026 ATM Share Program

TIPRANKS
·
Feb 24

Oric Pharmaceuticals - May Offer & Sell Shares of Common Stock of up to $200 Mln From Time to Time Through Jefferies - SEC Filing

THOMSON REUTERS
·
Feb 24

ORIC Pharmaceuticals Q4 EPS $(0.30) Beats $(0.37) Estimate

Benzinga Earnings
·
Feb 24